In Ophthalmology, no two eyes are the same, and no year is the same. The industry keeps evolving with new products emerging daily. To stand out, we prioritize our R&D to offer the best solutions and create IOLs with superior optics for better patient outcomes.
The start of 2024 displays what we believe in. We completed the clinical trial of Artiplus, our new flagship IOL with CTF-technology. Truly a big plus in the treatment of presbyopia, offering patients between 40-60 years clear vision at all distances. The results of the multi-centered international clinical trial were impressive, with a patient satisfaction rate of 99%(!). At the ESCRS in Barcelona, we celebrated a wonderful evening with leading experts from over the world to discuss to potential of the lens. We are eagerly looking forward to receiving CE approval in the second half of 2024.
We also launched Precizon Go. This new member of our Precizon Family, a line of premium cataract IOLs, offers enhanced intermediate vision without compromising distance. We already have seen that this lens performed excellently in both bench and market studies. The field outcomes even surpassed our expectations. Every week we are excited to hear amazing stories and receive great data from doctors. How did we achieve it? In this edition of OphTheRecord, we will tell you all about it.
The medical industry does not stand still and as we all know, sustainability is becoming an urgent matter. At Ophtec, we made significant investments in upgrading our production site to reduce our environmental impact. We have embedded sustainability as a key pillar in our company’s strategy. We asked Dr. Sjoerd Elferink to share his view on this important topic in (for) this edition of Oph The Record. We can only support his call: ‘We need to face this challenge together!’
.jpg)